For prostate cancer (online supplemental figure 2), the cumulative risks by age 80 were 31% (23% to 38%) for ATM PTV carriers and 25% (20% to 29%) for CHEK2 PTV carriers. This evidence concerns the gene CHEK2 and prostate carcinoma.